Selected Grants
2/3 CTSA K12 Program at Duke University
ResearchMentor · Awarded by National Institutes of Health · 2025 - 2030Stimulating Access to Research in Residency (StARR) - NIAID
Inst. Training Prgm or CMEPreceptor · Awarded by National Institute of Allergy and Infectious Diseases · 2018 - 2029The Duke Preparing Research scholars In bioMEdical sciences (PRIME): Cancer Research Program
ResearchPreceptor · Awarded by National Cancer Institute · 2023 - 2028Harnessing B Cells after Stem Cell Transplant to Produce Novel CAR-Ts
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2025 - 2027Duke Program of Training in Pulmonary ReSearch to Promote, Engage and Retain Academic Researchers (PROSPER)
Inst. Training Prgm or CMEPreceptor · Awarded by National Heart, Lung, and Blood Institute · 2022 - 2026The Role of the DNA Sensor AIM2 in B Cell Fate and Function After HCT
ResearchPrincipal Investigator · Awarded by Leukemia & Lymphoma Society · 2024 - 2026B Cell-Fibroblast Crosstalk Promotes Chronic GVHD of the Lung
ResearchMentor · Awarded by National Institute of Allergy and Infectious Diseases · 2024 - 2026Hematology & Transfusion Medicine (T32)
Inst. Training Prgm or CMEPreceptor · Awarded by National Heart, Lung, and Blood Institute · 1975 - 2026Pathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHD
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2026Basic Immunology Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2020 - 2025DABAT - DNA-sensing by AIM2 in activated B cells: novel targets to improve Allogeneic haematopoietic stem cell Transplantation
FellowshipPrincipal Investigator · Awarded by Universite de Bordeaux · 2020 - 2023T32 UNC - Duke Immunotherapy Training Program
Inst. Training Prgm or CMEPreceptor · Awarded by University of North Carolina - Chapel Hill · 2021 - 2022Medical Scientist Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 1997 - 2022Breaking B-Cell Tolerance to Produce Antibodies that Eradicate Leukemias and Lymphomas
ResearchPrincipal Investigator · Awarded by Department of Defense · 2018 - 2021The Notch2-BCR Axis: Targeting Drivers of B cell Fate in Chronic GVHD
ResearchPrincipal Investigator · Awarded by Leukemia & Lymphoma Society · 2015 - 2019Understanding Aberrant TLR7 Signaling in B Cells from Patients with Chronic GVHD
FellowshipPrincipal Investigator · Awarded by American Society for Blood and Marrow Transplantation · 2018 - 2019A Phase II of Entospletinib, a SYK Inhibitor, First line cGVHD patients
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2016 - 2019The Effects of Syk Blockade with GS-9973 on Immunity in a Murine Model of GVHD
ResearchPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2016 - 2018Improving Outcomes Assessment in cGVHD
ResearchPrincipal Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2015 - 2018BAFF-Driven Targeted Immunotherapy for Patients with Leukemia
ResearchPrincipal Investigator · Awarded by Department of Defense · 2011 - 2015BAFF Pathology: Novel Therapeutic Targets in Chronic Graft versus Host Disease
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2011 - 2015Fellowships, Gifts, and Supported Research
T32 Immunotherapy Duke-UNC ·
2018
Awarded by: NIH
Awarded to William McManigle MD in my lab
ASBMT Young Investigator Award ·
2018
Awarded by: American Society of Bone Marrow Transplantation
Awarded to Amy Suthers, PhD in my lab
Duke Scholar Award ·
2017
Awarded by: Duke University
External Relationships
- ASTCT (American Society of Transplantation and Cellular Therapy)
- Incyte Corporation
- Rigel Pharmaceuticals Inc advisory board once Jan 2020--COMPLETED; Rigel provides fostamatinib for our NIH-funded Duke clinical trial (I hold IND)
- Rigel Pharmaceuticals, Inc
- Sanofi
- nference
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.